• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

比哈尔邦黑热病(包括黑热病后皮肤利什曼病)的流行病学、临床及治疗特征

Epidemiological, clinical and therapeutic features of Bihar kala-azar (including post kala-azar dermal leishmaniasis).

作者信息

Thakur C P

出版信息

Trans R Soc Trop Med Hyg. 1984;78(3):391-8. doi: 10.1016/0035-9203(84)90131-7.

DOI:10.1016/0035-9203(84)90131-7
PMID:6087515
Abstract

This epidemic of kala-azar in Bihar, India, started from a small block and gradually spread to almost all of North Bihar. Vaishali was the district most affected, with the highest incidence rate of 5.9 per thousand in 1978. The epidemic spread more to the east than to the west. In 1977 there were 100,000 cases of kala-azar in Bihar and in Vaishali district the death rate was 28.7% of affected cases. It took five years to control the epidemic. 750 parasitologically confirmed cases of kala-azar were studied. The male:female ratio was 5.5:1. 63.4% of cases were aged 10 to 29 years. Clinical features were classical. Sodium stibogluconate, used as a first line drug, was effective in 92.6% of cases. By increasing the course of antimonial therapy from 10 to 20 days the relapse rate was reduced to 0.5% compared with 15% in the previous epidemic. Kala-azar patients who also had tuberculosis were treated with the antimonial and antituberculosis drugs concurrently and all cases recovered. 86 cases unresponsive to sodium stibogluconate were given pentamidine, which was effective in 93.4%. Side effects with sodium stibogluconate were minimal, but were common and serious with pentamidine. The need for a safer drug effective in cases which do not respond to antimony was very evident. 20 cases of post kala-azar dermal leishmaniasis (PKDL) were reviewed: two had no previous previous history of kala-azar. The relapse rate was higher in PKDL than in kala-azar.

摘要

印度比哈尔邦的黑热病疫情始于一个小街区,随后逐渐蔓延至北比哈尔邦的几乎所有地区。瓦伊沙利是受影响最严重的地区,1978年发病率高达千分之五点九。疫情向东蔓延的范围比向西更广。1977年,比哈尔邦有10万例黑热病病例,在瓦伊沙利地区,受影响病例的死亡率为28.7%。控制疫情花了五年时间。对750例经寄生虫学确诊的黑热病病例进行了研究。男女比例为5.5:1。63.4%的病例年龄在10至29岁之间。临床特征典型。作为一线药物使用的葡萄糖酸锑钠,在92.6%的病例中有效。通过将锑剂治疗疗程从10天增加到20天,复发率降至0.5%,而之前疫情中的复发率为15%。同时患有结核病的黑热病患者接受了锑剂和抗结核药物联合治疗,所有病例均康复。86例对葡萄糖酸锑钠无反应的病例使用了喷他脒,有效率为93.4%。葡萄糖酸锑钠的副作用极小,但喷他脒的副作用常见且严重。显然需要一种在对锑无反应的病例中有效的更安全药物。对20例黑热病后皮肤利什曼病(PKDL)病例进行了回顾:其中两例既往无黑热病病史。PKDL的复发率高于黑热病。

相似文献

1
Epidemiological, clinical and therapeutic features of Bihar kala-azar (including post kala-azar dermal leishmaniasis).比哈尔邦黑热病(包括黑热病后皮肤利什曼病)的流行病学、临床及治疗特征
Trans R Soc Trop Med Hyg. 1984;78(3):391-8. doi: 10.1016/0035-9203(84)90131-7.
2
Hepatitis B and C viral infections in Indian kala-azar patients receiving injectable anti-leishmanial drugs: a community-based study.接受注射用抗利什曼原虫药物治疗的印度黑热病患者中的乙型和丙型肝炎病毒感染:一项基于社区的研究。
Int J Infect Dis. 2000;4(4):203-8. doi: 10.1016/s1201-9712(00)90110-3.
3
Impact of amphotericin-B in the treatment of kala-azar on the incidence of PKDL in Bihar, India.两性霉素B治疗黑热病对印度比哈尔邦皮肤利什曼病发病率的影响。
Indian J Med Res. 2008 Jul;128(1):38-44.
4
Treatment of visceral leishmaniasis (kala-azar) with aminosidine (= paromomycin)-antimonial combinations, a pilot study in Bihar, India.氨基糖苷(=巴龙霉素)-锑剂联合治疗内脏利什曼病(黑热病):印度比哈尔邦的一项试点研究
Trans R Soc Trop Med Hyg. 1992 Nov-Dec;86(6):615-6. doi: 10.1016/0035-9203(92)90150-b.
5
Post-kala-azar dermal leishmaniasis in visceral leishmaniasis-endemic communities in Bihar, India.印度比哈尔邦内脏利什曼病流行地区的黑热病后皮肤利什曼病。
Trop Med Int Health. 2012 Nov;17(11):1345-8. doi: 10.1111/j.1365-3156.2012.03067.x. Epub 2012 Aug 12.
6
Improved kala-azar case management through implementation of health facility-based sentinel sites surveillance system in Bihar, India.通过在印度比哈尔邦实施基于卫生机构的哨点监测系统,改善黑热病病例管理。
PLoS Negl Trop Dis. 2021 Aug 24;15(8):e0009598. doi: 10.1371/journal.pntd.0009598. eCollection 2021 Aug.
7
Post-kala-azar dermal leishmaniasis in the Sudan: clinical presentation and differential diagnosis.苏丹的黑热病后皮肤利什曼病:临床表现与鉴别诊断
Br J Dermatol. 2000 Jul;143(1):136-43. doi: 10.1046/j.1365-2133.2000.03603.x.
8
[Methylglucamine antimoniate and sodium stibogluconate in the treatment of leishmaniasis. Study of 16 cases].[葡甲胺锑酸盐和葡萄糖酸锑钠治疗利什曼病。16例研究]
Pathol Biol (Paris). 1985 Jun;33(5 Pt 2):607-10.
9
Post kala-azar dermal leishmaniasis: a neglected aspect of kala-azar control programmes.黑热病后皮肤利什曼病:黑热病控制项目中被忽视的一个方面。
Ann Trop Med Parasitol. 1992 Aug;86(4):355-9. doi: 10.1080/00034983.1992.11812678.
10
Study of the outbreak of kala-azar epidemic in Bihar.比哈尔邦黑热病疫情爆发的研究。
J Assoc Physicians India. 1978 Jun;26(6):511-8.

引用本文的文献

1
Blood transfusion in the care of patients with visceral leishmaniasis: a review of practices in therapeutic efficacy studies.内脏利什曼病患者的输血护理:治疗疗效研究中实践的综述。
Trans R Soc Trop Med Hyg. 2024 Aug 5;118(8):481-490. doi: 10.1093/trstmh/trae018.
2
Haematological dynamics following treatment of visceral leishmaniasis: a protocol for systematic review and individual participant data (IPD) meta-analysis.治疗内脏利什曼病后血液学动态:系统评价和个体参与者数据(IPD)荟萃分析方案。
BMJ Open. 2023 Dec 14;13(12):e074841. doi: 10.1136/bmjopen-2023-074841.
3
Pyrimido[5,4-]pyrimidine-Based Compounds as a Novel Class of Antitrypanosomal and Antileishmanial Agents.
基于嘧啶并[5,4-]嘧啶的化合物作为一类新型抗锥虫和抗利什曼原虫药物。
ACS Med Chem Lett. 2022 Aug 9;13(9):1427-1433. doi: 10.1021/acsmedchemlett.2c00170. eCollection 2022 Sep 8.
4
Gender disparity in cases enrolled in clinical trials of visceral leishmaniasis: A systematic review and meta-analysis.临床试验中内脏利什曼病病例的性别差异:系统评价和荟萃分析。
PLoS Negl Trop Dis. 2021 Mar 16;15(3):e0009204. doi: 10.1371/journal.pntd.0009204. eCollection 2021 Mar.
5
Visceral leishmaniasis cyclical trends in Bihar, India - implications for the elimination programme.印度比哈尔邦内脏利什曼病的周期性趋势——对消除计划的影响
Gates Open Res. 2018 Feb 21;2:10. doi: 10.12688/gatesopenres.12793.1.
6
Post-kala-azar dermal leishmaniasis in the Indian subcontinent: A threat to the South-East Asia Region Kala-azar Elimination Programme.印度次大陆的黑热病后皮肤利什曼病:对东南亚区域消除黑热病规划的一个威胁
PLoS Negl Trop Dis. 2017 Nov 16;11(11):e0005877. doi: 10.1371/journal.pntd.0005877. eCollection 2017 Nov.
7
Is elimination of kala-azar feasible by 2017?到2017年消除黑热病是否可行?
Indian J Med Res. 2016 Dec;144(6):799-802. doi: 10.4103/ijmr.IJMR_335_16.
8
Current challenges in treatment options for visceral leishmaniasis in India: a public health perspective.从公共卫生角度看印度内脏利什曼病治疗方案的当前挑战
Infect Dis Poverty. 2016 Mar 8;5:19. doi: 10.1186/s40249-016-0112-2.
9
Clinicopathological and Immunological Changes in Indian Post Kala-Azar Dermal Leishmaniasis (PKDL) Cases in relation to Treatment: A Retrospective Study.印度黑热病后皮肤利什曼病(PKDL)病例与治疗相关的临床病理和免疫学变化:一项回顾性研究。
Biomed Res Int. 2015;2015:745062. doi: 10.1155/2015/745062. Epub 2015 May 18.
10
New challenges in the epidemiology and treatment of visceral leishmaniasis in periurban areas.城市周边地区内脏利什曼病流行病学与治疗的新挑战
Drug Dev Res. 2011 Sep;72(6):451-462. doi: 10.1002/ddr.20452.